Publications by authors named "R Podlasin"
Association between Liver Damage and Disease Progression Markers with Mortality Risk and Mechanical Ventilation in Hospitalized COVID-19 Patients: A Nationwide Retrospective SARSTer Study.
Viruses
September 2024
Article Synopsis
- - Background information indicates that liver damage is a key factor in acute COVID-19 cases, and existing liver conditions worsen patient outcomes.
- - A study analyzed data from 7,444 patients to assess liver damage markers and their links to mortality and the need for mechanical ventilation (MV).
- - Results showed that higher levels of specific liver enzymes and scores (like ALT, AST, and FIB-4) correlate with greater mortality risk, while LDH was especially predictive for needing MV, highlighting the importance of monitoring liver function in COVID-19 patients.
Introduction: COVID-19 is a disease characterized by high in-hospital mortality, which seems to be dependent on many predisposing factors.
Objectives: The aim of this study was to analyze the clinical symptoms, abnormalities in the results of laboratory tests, and coexisting chronic diseases that independently affected the risk of in-hospital mortality in patients with COVID-19.
Patients And Methods: We analyzed the records of patients with COVID-19 who were hospitalized from 6 March 2020 to 30 November 2021.
Leprosy - neglected tropical disease in Pygmies inhabiting Central African Republic.
Ann Agric Environ Med
September 2023
Leprosy is a neglected tropical disease that is still present worldwide despite efforts aimed at elimination of the disease. The BaAka Pygmy community inhabiting rural areas in the Central African Republic is one of the most leprosy-vulnerable populations. The aim of the study was to assess the prevalence of leprosy in the BaAka Pygmy population.
View Article and Find Full Text PDFPatients with systemic autoimmune rheumatic disease (SARD) have increased susceptibility to viral infections, including SARS-CoV-2. The aim of this study was to analyse the SARD patient population with COVID-19 (coronavirus disease 2019) in terms of baseline characteristics, severity, course and outcomes of the disease compared with the non-SARD group, and to identify factors associated with prognosis, including remdesivir therapy efficacy. Retrospective study comprised 8220 COVID-19 cases from the SARSTer database, including 185 with SARD.
View Article and Find Full Text PDFData on the use of remdesivir, the first antiviral agent against SARS-CoV-2, are limited in oncologic patients. We aimed to analyze contributing factors for mortality in patients with malignancies in the real-world CSOVID-19 study. In total, 222 patients with active oncological disorders were selected from a nationwide COVID-19 study of 4890 subjects.
View Article and Find Full Text PDF